Bioenvision to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference

Bioenvision, Inc. (Nasdaq:BIVN) announced today that
Hugh Griffith, Chief Operating Officer of the Company, is scheduled to
present at the Rodman & Renshaw 3rd Annual Global Healthcare
Conference on Monday, May 15, 2006 at 5:45 pm local time, at the Le
Meridien Beach Plaza Hotel in Monte Carlo, Monaco. A live webcast of
this presentation will be available via
http://wsw.com/webcast/rrshq8/bivn and will be archived and available
for replay after the presentation for a limited time.

   About Bioenvision

   Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Clofarabine (in co-development
with Genzyme Corporation), Modrenal(R) (for which Bioenvision has
obtained regulatory approval for marketing in the United Kingdom for
the treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products in clinical trials.
Bioenvision is also developing Suvus for chronic Hepatitis C and
anti-infective technologies, including the OLIGON technology; an
advanced biomaterial that has been incorporated into various FDA
approved medical devices. For more information on Bioenvision please
visit our Web site at www.bioenvision.com.
   Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.